Inactive Instrument

Analyst Reco. Sierra Oncology, Inc.

Equities

Oppenheimer Downgrades Sierra Oncology to Perform From Outperform, Adjusts Price Target to $55 From $45	14/04/22	MT
Jefferies Downgrades Sierra Oncology to Hold From Buy, Adjusts Price Target to $55 From $39	14/04/22	MT
HC Wainwright Downgrades Sierra Oncology to Neutral from Buy, Adjusts Price target to $55 from $51	13/04/22	MT
FTSE Edges Lower, March Inflation Data Seen Securing Another BoE Rate Rise in May	13/04/22	DJ
Oppenheimer Adjusts Sierra Oncology Price Target to $45 From $38, Maintains Outperform Rating	14/03/22	MT
HC Wainwright Adjusts Sierra Oncology's Price Target to $51 From $35, Reiterates Buy Rating	31/01/22	MT
Oppenheimer Adjusts Sierra Oncology's Price Target to $38 From $32, Maintains Outperform Rating	27/01/22	MT
Oppenheimer Adjusts Sierra Oncology's Price Target to $32 From $29, Maintains Outperform Rating	19/01/22	MT
Cantor Fitzgerald Adjusts Sierra Oncology's Price Target to $39 From $33, Maintains Overweight Rating	30/11/21	MT
HC Wainwright Adjusts Sierra Oncology PT to $35 From $29, Maintains Buy Rating	05/11/21	MT
SIERRA ONCOLOGY : Cantor Fitzgerald Starts Sierra Oncology at Overweight with $33 Price Target	27/09/21	MT
SIERRA ONCOLOGY : Oppenheimer Adjusts Sierra Oncology PT to $29 From $27, Maintains Outperform Rating	17/12/20	MT
SIERRA ONCOLOGY : HC Wainwright Starts Sierra Oncology at Buy With $29 Price Target	11/12/20	MT
Sierra Oncology, Inc. Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib	03/12/18	CI

No results for this search